dronabinol has been researched along with Parkinsonian Disorders in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Burger, F; Sidoroff, V; Szejko, N; Wenning, GK | 1 |
Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
Bok, E; Chung, YC; Huh, SH; Jin, BK; Kim, SR; Kim, YS; Maeng, S; Park, JY; Park, SH; Yoon, SH | 1 |
Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 1 |
Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M | 1 |
Jongsma, MJ; Olivier, B; Philippens, IH; van Vliet, SA; Vanwersch, RA | 1 |
6 other study(ies) available for dronabinol and Parkinsonian Disorders
Article | Year |
---|---|
Case Report: Secondary bilateral parkinsonism and dystonia treated with dronabinol.
Topics: Adult; Basal Ganglia; Dronabinol; Dystonia; Dystonic Disorders; Humans; Parkinsonian Disorders | 2020 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoxazines; Cells, Cultured; Coculture Techniques; Corpus Striatum; Dopamine Agents; Dronabinol; Growth Inhibitors; Male; Mice; Mice, Inbred C57BL; Microglia; Morpholines; Naphthalenes; Neurons; Neurotoxins; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Substantia Nigra | 2011 |
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Glutamic Acid; Glycerides; Hydrolysis; In Vitro Techniques; Membrane Potentials; Neurons; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Synaptic Transmission | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug | 2002 |
Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Callithrix; Disease Models, Animal; Dronabinol; Female; Male; Modafinil; Parkinsonian Disorders | 2008 |